Review

streptococcus pneumoniae american type culture collection (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC streptococcus pneumoniae american type culture collection

Minimum inhibitory concentrations (MICs) of azeliragon, penicillin, tetracycline, and vancomycin against clinical S. <t>pneumoniae</t> isolates were determined using the broth microdilution method. MIC 50 [the lowest concentration inhibiting 50% of isolates; (A) ] and MIC 90 [the lowest concentration inhibiting 90% of isolates; (B) ] were calculated. Values shown above the bars indicate the corresponding MIC 50 or MIC 90 (μg/mL). Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3).

Streptococcus Pneumoniae American Type Culture Collection, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 261 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/streptococcus pneumoniae american type culture collection/product/ATCC
Average 97 stars, based on 261 article reviews

streptococcus pneumoniae american type culture collection - by Bioz Stars, 2026-05

97/100 stars

Images

1) Product Images from "Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models"

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

Journal: Frontiers in Medicine

doi: 10.3389/fmed.2026.1793580

Minimum inhibitory concentrations (MICs) of azeliragon, penicillin, tetracycline, and vancomycin against clinical S. pneumoniae isolates were determined using the broth microdilution method. MIC 50 [the lowest concentration inhibiting 50% of isolates; (A) ] and MIC 90 [the lowest concentration inhibiting 90% of isolates; (B) ] were calculated. Values shown above the bars indicate the corresponding MIC 50 or MIC 90 (μg/mL). Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3).

Figure Legend Snippet: Minimum inhibitory concentrations (MICs) of azeliragon, penicillin, tetracycline, and vancomycin against clinical S. pneumoniae isolates were determined using the broth microdilution method. MIC 50 [the lowest concentration inhibiting 50% of isolates; (A) ] and MIC 90 [the lowest concentration inhibiting 90% of isolates; (B) ] were calculated. Values shown above the bars indicate the corresponding MIC 50 or MIC 90 (μg/mL). Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3).

Techniques Used: Concentration Assay

Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

Figure Legend Snippet: Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

Techniques Used: In Vitro, Incubation, Bacteria, Cell Culture, Control

Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

Figure Legend Snippet: Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

Techniques Used: Activity Assay, Disruption, Bacteria, Cell Culture, Control, Staining, Comparison

Effects of azeliragon on membrane integrity and oxidative stress in S. pneumoniae . (A) Propidium iodide (PI) staining was used to assess membrane permeability. Bacteria were treated under control conditions or with azeliragon (4× MIC) or vancomycin (4× MIC). Fluorescence intensity (A.U.) was measured to evaluate membrane integrity. (B) Intracellular oxidative stress was assessed using a reactive oxygen species (ROS) fluorescent probe. Bacteria were treated as indicated, and ROS fluorescence intensity (A.U.) was quantified. Data were presented as mean ± SD. Group comparisons were performed using one-way ANOVA followed by Tukey’s multiple-comparison test. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, * p < 0.05, ** p < 0.01.

Figure Legend Snippet: Effects of azeliragon on membrane integrity and oxidative stress in S. pneumoniae . (A) Propidium iodide (PI) staining was used to assess membrane permeability. Bacteria were treated under control conditions or with azeliragon (4× MIC) or vancomycin (4× MIC). Fluorescence intensity (A.U.) was measured to evaluate membrane integrity. (B) Intracellular oxidative stress was assessed using a reactive oxygen species (ROS) fluorescent probe. Bacteria were treated as indicated, and ROS fluorescence intensity (A.U.) was quantified. Data were presented as mean ± SD. Group comparisons were performed using one-way ANOVA followed by Tukey’s multiple-comparison test. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, * p < 0.05, ** p < 0.01.

Techniques Used: Membrane, Staining, Permeability, Bacteria, Control, Fluorescence, Comparison

In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

Figure Legend Snippet: In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

Techniques Used: In Vivo, Infection, Drug discovery, Control

Effects of azeliragon on tissue bacterial burden and inflammatory cytokines in a non-lethal mouse model of S. pneumoniae infection. (A) Bacterial loads in blood (CFU/mL). (B) Bacterial loads in lung tissue (CFU/g). (C) Serum interleukin-6 (IL-6) levels (pg/mL). (D) Serum tumor necrosis factor-α (TNF-α) levels (pg/mL). Mice received vehicle control, bacterial control, azeliragon (10 mg/kg), or vancomycin (10 mg/kg). Blood and lung samples were collected for quantitative bacterial culture. Serum cytokine levels were measured by ELISA. Data are presented as mean ± SD. Group comparisons were performed using one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, ** p < 0.01 and *** p < 0.001.

Figure Legend Snippet: Effects of azeliragon on tissue bacterial burden and inflammatory cytokines in a non-lethal mouse model of S. pneumoniae infection. (A) Bacterial loads in blood (CFU/mL). (B) Bacterial loads in lung tissue (CFU/g). (C) Serum interleukin-6 (IL-6) levels (pg/mL). (D) Serum tumor necrosis factor-α (TNF-α) levels (pg/mL). Mice received vehicle control, bacterial control, azeliragon (10 mg/kg), or vancomycin (10 mg/kg). Blood and lung samples were collected for quantitative bacterial culture. Serum cytokine levels were measured by ELISA. Data are presented as mean ± SD. Group comparisons were performed using one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, ** p < 0.01 and *** p < 0.001.

Techniques Used: Infection, Control, Enzyme-linked Immunosorbent Assay, Comparison

Image Search Results

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Minimum inhibitory concentrations (MICs) of azeliragon, penicillin, tetracycline, and vancomycin against clinical S. pneumoniae isolates were determined using the broth microdilution method. MIC 50 [the lowest concentration inhibiting 50% of isolates; (A) ] and MIC 90 [the lowest concentration inhibiting 90% of isolates; (B) ] were calculated. Values shown above the bars indicate the corresponding MIC 50 or MIC 90 (μg/mL). Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3).

Article Snippet: Streptococcus pneumoniae American Type Culture Collection (ATCC) 49,619 and the clinical isolates 1057 and 1044 were used for in vitro antimicrobial assays, mechanistic studies, and in vivo infection models.

Techniques: Concentration Assay

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

Techniques: In Vitro, Incubation, Bacteria, Cell Culture, Control

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

Techniques: Activity Assay, Disruption, Bacteria, Cell Culture, Control, Staining, Comparison

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Effects of azeliragon on membrane integrity and oxidative stress in S. pneumoniae . (A) Propidium iodide (PI) staining was used to assess membrane permeability. Bacteria were treated under control conditions or with azeliragon (4× MIC) or vancomycin (4× MIC). Fluorescence intensity (A.U.) was measured to evaluate membrane integrity. (B) Intracellular oxidative stress was assessed using a reactive oxygen species (ROS) fluorescent probe. Bacteria were treated as indicated, and ROS fluorescence intensity (A.U.) was quantified. Data were presented as mean ± SD. Group comparisons were performed using one-way ANOVA followed by Tukey’s multiple-comparison test. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, * p < 0.05, ** p < 0.01.

Techniques: Membrane, Staining, Permeability, Bacteria, Control, Fluorescence, Comparison

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

Techniques: In Vivo, Infection, Drug discovery, Control

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Effects of azeliragon on tissue bacterial burden and inflammatory cytokines in a non-lethal mouse model of S. pneumoniae infection. (A) Bacterial loads in blood (CFU/mL). (B) Bacterial loads in lung tissue (CFU/g). (C) Serum interleukin-6 (IL-6) levels (pg/mL). (D) Serum tumor necrosis factor-α (TNF-α) levels (pg/mL). Mice received vehicle control, bacterial control, azeliragon (10 mg/kg), or vancomycin (10 mg/kg). Blood and lung samples were collected for quantitative bacterial culture. Serum cytokine levels were measured by ELISA. Data are presented as mean ± SD. Group comparisons were performed using one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, ** p < 0.01 and *** p < 0.001.

Techniques: Infection, Control, Enzyme-linked Immunosorbent Assay, Comparison

Antimicrobiol Susceptibility patterns of S. pneumoniae isolated among children attending primary schools in Bisidimo Eastern Ethiopia 2023.

Journal: PLOS One

Article Title: Nasopharyngeal carriage of Streptococcus pneumoniae, its associated factors, and antimicrobial susceptibility patterns among school children in Babile district, eastern Ethiopia

doi: 10.1371/journal.pone.0337950

Figure Lengend Snippet: Antimicrobiol Susceptibility patterns of S. pneumoniae isolated among children attending primary schools in Bisidimo Eastern Ethiopia 2023.

Article Snippet: S. pneumoniae American Type Culture Collection (ATCC 49,619) [ ] was used as a positive control strain on each procedure.

Techniques: Isolation

Review

Structured Review

Images

1) Product Images from "Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models"

Similar Products

Image Search Results